Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals reported strong first-quarter 2026 growth driven by its MASH drug Rezdiffra. Net revenues reached $311.3 million, up 127% from $137.3 million a year earlier, reflecting broad physician adoption and high patient demand.
Operating expenses rose to $404.1 million, including $54.3 million of one-time business development costs and $34.0 million of non-cash stock-based compensation. The company reported a net loss of $94.4 million, or $3.25 per share, compared with a $73.2 million loss in the prior-year quarter.
Madrigal ended March 31, 2026 with $817.9 million in cash, cash equivalents, restricted cash and marketable securities. More than 42,250 patients were on Rezdiffra as of March 31, 2026, and management highlighted that Rezdiffra has achieved blockbuster status on a trailing 12‑month net sales basis.
Madrigal Pharmaceuticals, Inc. reported a change in how its Board of Directors is classified, without changing who serves on the Board. On April 22, 2026, the Board rebalanced the membership of its three director classes so each class will be as evenly sized as possible after the 2026 Annual Meeting of Stockholders on June 17, 2026.
To accomplish this, Julian C. Baker and Daniel J. Brennan were reclassified as Class I directors, whose terms expire at the 2026 Annual Meeting. Each resigned from his prior Class III and Class II seat, respectively, solely to allow simultaneous reappointment as a Class I director, and their Board service is considered uninterrupted. Their committee assignments did not change, and both, along with James Daly, have been nominated for re-election at the 2026 Annual Meeting.
Madrigal Pharmaceuticals calls a virtual 2026 annual meeting on June 17 to elect three Class I directors, hold an advisory vote on executive pay, ratify PwC as auditor, and seek approval of a new 2026 Stock Plan and 2026 Employee Stock Purchase Plan.
The company highlights a breakout first commercial year for MASH drug Rezdiffra, with 2025 net revenue of $958.4 million, up sharply from 2024, and more than 36,250 patients on therapy by year-end. Management reports Rezdiffra sales running at over $1 billion on an annualized quarterly basis and notes new patent protection expected into 2045, along with expansion into Germany and development of more than ten complementary MASH programs.
The proxy emphasizes strong stockholder alignment, including a prior say‑on‑pay approval of about 99%, pay-for-performance design with a heavy mix of at-risk equity (options, RSUs and PSUs tied to relative total stockholder return), and standard governance practices such as an independent chair, fully independent key committees and robust insider trading, hedging and pledging restrictions.
Madrigal Pharmaceuticals Inc Schedule 13G/A Amendment No. 5: The Vanguard Group reports a post-realignment disaggregation of holdings and states it beneficially owns 0 shares (0%) of Common Stock. The filing references an internal realignment on January 12, 2026 and is signed on 03/27/2026.
Madrigal Pharmaceuticals EVP and CFO Mardi Dier reported both stock sales and new equity awards. On March 6, 2026, she sold a total of 1,982 shares of common stock in multiple open-market transactions at prices generally in the low-to-mid $400s per share. One sale was made by the company to cover tax withholding on vesting restricted stock units, and certain sales were made under a pre-established Rule 10b5-1 trading plan adopted on September 2, 2025.
On March 4, 2026, she received 5,215 restricted stock units and an option for 6,519 shares. The restricted stock units vest in four equal annual installments on March 4 of 2027, 2028, 2029, and 2030, while the option vests 25% on March 4, 2027, with the remainder vesting 6.25% at the end of each following three-month period, subject to continued service.
Madrigal Pharmaceuticals insider transaction notice (Form 144)
The filing shows reported dispositions of Common Stock tied to an executive account and restricted stock unit vesting. It lists two recent sales by Mardi Dier: 1,336 shares on 03/06/2026 for $586,958.24 and 1,183 shares on 03/02/2026 for $505,389.43. The document also records 646 shares associated with a Restricted Stock Unit vesting dated 03/06/2026, with an aggregate amount of $283,813.64 noted in the brokerage line.
Madrigal Pharmaceuticals President and CEO William John Sibold reported a mix of equity grants and a small share sale. On March 4, 2026, he received 18,743 stock options and 14,995 restricted stock units, both granted at $0.0000 per share and scheduled to vest in installments through 2030 subject to continued service.
On March 6, 2026, 1,663 shares of common stock were sold at an average price of $431.94 per share. According to the disclosure, this sale was executed by Madrigal Pharmaceuticals on Sibold’s behalf solely to cover tax withholding obligations tied to restricted stock unit vesting and was automatic rather than at his discretion. After these transactions, he directly held 161,829 shares of common stock and 18,743 stock options.
Madrigal Pharmaceuticals insider sale notice: 1,663 shares of Common Stock are listed for sale through Morgan Stanley Smith Barney LLC with an aggregate value shown as $730,622.42, dated 03/06/2026. The filing also records prior sales of 1,577 shares on 01/26/2026 for $776,546.34. Shares outstanding are shown as 22,939,969 as of 03/06/2026.
Madrigal Pharmaceuticals’ general counsel Kelley Shannon reported a mix of equity awards and a small share sale. On March 4, 2026, she received 4,017 shares of common stock as a grant of restricted stock units that vest in four equal annual installments on March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, contingent on continued service. She was also granted a stock option for 5,022 shares that vests 25% on March 4, 2027 and 6.25% every three months thereafter, also subject to continued service. On March 6, 2026, 360 shares of common stock were sold at $431.94 per share by the company on her behalf solely to cover tax withholding from RSU vesting, an automatic transaction, leaving her with 12,138 shares of common stock held directly.